Human parathyroid hormone-related peptide measurement in the lung cancer patients

J. Chang, S. K. Kim, Sungkil Lim, H. L. Lee, S. K. Kim, W. Y. Lee

Research output: Contribution to journalArticle

Abstract

Background: Parathyroid hormone-related protein (PTHrp) was first identified as the cause of hypercalcemia in malignancy. Hypercalcemia can be found in malignancy, especially in the epidermoid carcinoma of the lung, even without extensive metastases to the bones. The application of sensitive assays for PTHrp may help in the early diagnosis of lung cancer, in the monitoring of treatment and in the detection of recurrence. Method: Serum PTHrp was measured by radioimmunoassay detecting the N-terminal 1~34 peptide of human PTHrp (PTHrp 1-34) in 63 histologically confirmed lung cancer patients and 22 healthy controls. Result: Serum PTHrp (mean ± S.E.) was 312 ± 68.9 pg/ml in 63 lung cancer patients and 158 ± 38.2 pg/ml in 22 controls (p > 0.05). PTHrp was 356 ± 103.9 pg/ml in 34 epidermoid carcinoma patients, 281 ± 148.7 pg/ml in 15 adenocarcinoma patients and 316 ± 140.8 pg/ml in 9 small cell carcinoma patients. In epidermoid carcinoma patients, PTHrp was 570 ± 472.3 pg/ml in stage II (n = 3; p < 0.05 vs controls), 166 ± 22.4 pg/ml in stage IIIa (n = 9), 282 ± 113.3 pg/ml in stage IIIb (n = 12) and 668 ± 367.9 pg/ml in stage IV (n = 9; p < 0.05 vs controls). PTHrp was significantly increased in 8 epidermoid carcinoma patients with bone metastases (1526 ± 811.2 pg/ml; p < 0.0005 vs controls). Hypercalcemia was observed in an epidermoid carcinoma patient whose PTHrp value was 244 pg/ml. Conclusion: The serum PTHrp was increased in advanced epidermoid carcinoma patients even without hypercalcemia. The measurement of PTHrp may be not helpful in the early diagnosis of lung cancer. But the lung cancer should be suspected in the marked elevation of PTHrp. It may be of value in detecting patients of advanced diseases with bone metastases or patients who might develop the malignancy associated hypercalcemia.

Original languageEnglish
Pages (from-to)855-861
Number of pages7
JournalTuberculosis and Respiratory Diseases
Volume42
Issue number6
DOIs
Publication statusPublished - 1995 Jan 1

Fingerprint

Parathyroid Hormone-Related Protein
Lung Neoplasms
Hypercalcemia
Squamous Cell Carcinoma
Blood Proteins
Neoplasm Metastasis
Early Detection of Cancer
human PTH protein
Bone and Bones
Neoplasms
Small Cell Carcinoma
Bone Diseases
Radioimmunoassay
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Chang, J. ; Kim, S. K. ; Lim, Sungkil ; Lee, H. L. ; Kim, S. K. ; Lee, W. Y. / Human parathyroid hormone-related peptide measurement in the lung cancer patients. In: Tuberculosis and Respiratory Diseases. 1995 ; Vol. 42, No. 6. pp. 855-861.
@article{f0bb8a9107d44bf3ac33c6e3bbb5eaee,
title = "Human parathyroid hormone-related peptide measurement in the lung cancer patients",
abstract = "Background: Parathyroid hormone-related protein (PTHrp) was first identified as the cause of hypercalcemia in malignancy. Hypercalcemia can be found in malignancy, especially in the epidermoid carcinoma of the lung, even without extensive metastases to the bones. The application of sensitive assays for PTHrp may help in the early diagnosis of lung cancer, in the monitoring of treatment and in the detection of recurrence. Method: Serum PTHrp was measured by radioimmunoassay detecting the N-terminal 1~34 peptide of human PTHrp (PTHrp 1-34) in 63 histologically confirmed lung cancer patients and 22 healthy controls. Result: Serum PTHrp (mean ± S.E.) was 312 ± 68.9 pg/ml in 63 lung cancer patients and 158 ± 38.2 pg/ml in 22 controls (p > 0.05). PTHrp was 356 ± 103.9 pg/ml in 34 epidermoid carcinoma patients, 281 ± 148.7 pg/ml in 15 adenocarcinoma patients and 316 ± 140.8 pg/ml in 9 small cell carcinoma patients. In epidermoid carcinoma patients, PTHrp was 570 ± 472.3 pg/ml in stage II (n = 3; p < 0.05 vs controls), 166 ± 22.4 pg/ml in stage IIIa (n = 9), 282 ± 113.3 pg/ml in stage IIIb (n = 12) and 668 ± 367.9 pg/ml in stage IV (n = 9; p < 0.05 vs controls). PTHrp was significantly increased in 8 epidermoid carcinoma patients with bone metastases (1526 ± 811.2 pg/ml; p < 0.0005 vs controls). Hypercalcemia was observed in an epidermoid carcinoma patient whose PTHrp value was 244 pg/ml. Conclusion: The serum PTHrp was increased in advanced epidermoid carcinoma patients even without hypercalcemia. The measurement of PTHrp may be not helpful in the early diagnosis of lung cancer. But the lung cancer should be suspected in the marked elevation of PTHrp. It may be of value in detecting patients of advanced diseases with bone metastases or patients who might develop the malignancy associated hypercalcemia.",
author = "J. Chang and Kim, {S. K.} and Sungkil Lim and Lee, {H. L.} and Kim, {S. K.} and Lee, {W. Y.}",
year = "1995",
month = "1",
day = "1",
doi = "10.4046/trd.1995.42.6.855",
language = "English",
volume = "42",
pages = "855--861",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "6",

}

Human parathyroid hormone-related peptide measurement in the lung cancer patients. / Chang, J.; Kim, S. K.; Lim, Sungkil; Lee, H. L.; Kim, S. K.; Lee, W. Y.

In: Tuberculosis and Respiratory Diseases, Vol. 42, No. 6, 01.01.1995, p. 855-861.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Human parathyroid hormone-related peptide measurement in the lung cancer patients

AU - Chang, J.

AU - Kim, S. K.

AU - Lim, Sungkil

AU - Lee, H. L.

AU - Kim, S. K.

AU - Lee, W. Y.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background: Parathyroid hormone-related protein (PTHrp) was first identified as the cause of hypercalcemia in malignancy. Hypercalcemia can be found in malignancy, especially in the epidermoid carcinoma of the lung, even without extensive metastases to the bones. The application of sensitive assays for PTHrp may help in the early diagnosis of lung cancer, in the monitoring of treatment and in the detection of recurrence. Method: Serum PTHrp was measured by radioimmunoassay detecting the N-terminal 1~34 peptide of human PTHrp (PTHrp 1-34) in 63 histologically confirmed lung cancer patients and 22 healthy controls. Result: Serum PTHrp (mean ± S.E.) was 312 ± 68.9 pg/ml in 63 lung cancer patients and 158 ± 38.2 pg/ml in 22 controls (p > 0.05). PTHrp was 356 ± 103.9 pg/ml in 34 epidermoid carcinoma patients, 281 ± 148.7 pg/ml in 15 adenocarcinoma patients and 316 ± 140.8 pg/ml in 9 small cell carcinoma patients. In epidermoid carcinoma patients, PTHrp was 570 ± 472.3 pg/ml in stage II (n = 3; p < 0.05 vs controls), 166 ± 22.4 pg/ml in stage IIIa (n = 9), 282 ± 113.3 pg/ml in stage IIIb (n = 12) and 668 ± 367.9 pg/ml in stage IV (n = 9; p < 0.05 vs controls). PTHrp was significantly increased in 8 epidermoid carcinoma patients with bone metastases (1526 ± 811.2 pg/ml; p < 0.0005 vs controls). Hypercalcemia was observed in an epidermoid carcinoma patient whose PTHrp value was 244 pg/ml. Conclusion: The serum PTHrp was increased in advanced epidermoid carcinoma patients even without hypercalcemia. The measurement of PTHrp may be not helpful in the early diagnosis of lung cancer. But the lung cancer should be suspected in the marked elevation of PTHrp. It may be of value in detecting patients of advanced diseases with bone metastases or patients who might develop the malignancy associated hypercalcemia.

AB - Background: Parathyroid hormone-related protein (PTHrp) was first identified as the cause of hypercalcemia in malignancy. Hypercalcemia can be found in malignancy, especially in the epidermoid carcinoma of the lung, even without extensive metastases to the bones. The application of sensitive assays for PTHrp may help in the early diagnosis of lung cancer, in the monitoring of treatment and in the detection of recurrence. Method: Serum PTHrp was measured by radioimmunoassay detecting the N-terminal 1~34 peptide of human PTHrp (PTHrp 1-34) in 63 histologically confirmed lung cancer patients and 22 healthy controls. Result: Serum PTHrp (mean ± S.E.) was 312 ± 68.9 pg/ml in 63 lung cancer patients and 158 ± 38.2 pg/ml in 22 controls (p > 0.05). PTHrp was 356 ± 103.9 pg/ml in 34 epidermoid carcinoma patients, 281 ± 148.7 pg/ml in 15 adenocarcinoma patients and 316 ± 140.8 pg/ml in 9 small cell carcinoma patients. In epidermoid carcinoma patients, PTHrp was 570 ± 472.3 pg/ml in stage II (n = 3; p < 0.05 vs controls), 166 ± 22.4 pg/ml in stage IIIa (n = 9), 282 ± 113.3 pg/ml in stage IIIb (n = 12) and 668 ± 367.9 pg/ml in stage IV (n = 9; p < 0.05 vs controls). PTHrp was significantly increased in 8 epidermoid carcinoma patients with bone metastases (1526 ± 811.2 pg/ml; p < 0.0005 vs controls). Hypercalcemia was observed in an epidermoid carcinoma patient whose PTHrp value was 244 pg/ml. Conclusion: The serum PTHrp was increased in advanced epidermoid carcinoma patients even without hypercalcemia. The measurement of PTHrp may be not helpful in the early diagnosis of lung cancer. But the lung cancer should be suspected in the marked elevation of PTHrp. It may be of value in detecting patients of advanced diseases with bone metastases or patients who might develop the malignancy associated hypercalcemia.

UR - http://www.scopus.com/inward/record.url?scp=0029556250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029556250&partnerID=8YFLogxK

U2 - 10.4046/trd.1995.42.6.855

DO - 10.4046/trd.1995.42.6.855

M3 - Article

AN - SCOPUS:0029556250

VL - 42

SP - 855

EP - 861

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 6

ER -